Page 8 - Margaret Gandolfo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Margaret gandolfo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Margaret Gandolfo Today - Breaking & Trending Today

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
Cellectis Inc.; Cytovia Therapeutics, Inc.
New York, New York, UNITED STATES
CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. ....

New York , United States , Israel General , France General , North Carolina , United Kingdom , Simon Harnest , Chris Maggos , Anna Baran Djokovic , Margaret Gandolfo , Conor Mcgoldrick , Daniel Teper , York Stem Cell Foundation , Cytovia Therapeutics Inc , Hebrew University Of Jerusalem , University Of California San Francisco , Zeno Group , Natural Killer , Chimeric Antigen Receptor , Euronext Growth , Nasdaq Global Market , Chimeric Antigen Receptors , California San Francisco , New York Stem Cell Foundation , Hebrew University , Cytovia Therapeutics ,

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived  Natural Killer Cells Paris Stock Exchange:ALCLS

(MENAFN - GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells.
The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN® gene-edited iPSC-derived NK products ( partnership products ). Cellectis will also receive single-digit royalty payments on the net sales of all partnered produc ....

New York , United States , Israel General , France General , North Carolina , United Kingdom , Simon Harnest , Chris Maggos , Anna Baran Djokovic , Margaret Gandolfo , Conor Mcgoldrick , Daniel Teper , York Stem Cell Foundation , Securities Exchange Commission , Cytovia Therapeutics Inc , Hebrew University Of Jerusalem , University Of California San Francisco , Zeno Group , Natural Killer , Chimeric Antigen Receptor , Euronext Growth , Nasdaq Global Market , Chimeric Antigen Receptors , California San Francisco , New York Stem Cell Foundation , Hebrew University ,